Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | Filing |
| 2024-11-14 3:36 pm Sale | 13G | SURMODICS INC SRDX | Soleus Capital Master Fund L.P. | 637,698 4.500% | -134,002 (-17.36%) | View |
| 2024-11-14 3:35 pm Purchase | 13G | Organogenesis Holdings Inc. ORGO | Soleus Capital Master Fund L.P. | 11,839,876 8.900% | 2,876,876 (+32.10%) | View |
| 2024-11-14 3:35 pm Sale | 13G | IRADIMED CORP IRMD | Soleus Capital Master Fund L.P. | 1,000 0.000% | -642,206 (-99.84%) | View |
| 2024-11-14 3:34 pm Sale | 13G | VYNE Therapeutics Inc. VYNE | Soleus Capital Master Fund L.P. | 0 0.000% | -703,868 (Position Closed) | View |
| 2024-11-14 3:33 pm Purchase | 13G | RIGEL PHARMACEUTICALS INC RIGL | Soleus Capital Master Fund L.P. | 934,788 5.300% | 934,788 (New Position) | View |
| 2024-11-14 3:31 pm Purchase | 13G | AXOGEN, INC. AXGN | Soleus Capital Master Fund L.P. | 3,005,943 6.800% | 410,128 (+15.80%) | View |
| 2024-11-14 3:30 pm Purchase | 13G | Terns Pharmaceuticals Inc. TERN | Soleus Capital Master Fund L.P. | 6,223,544 7.300% | 2,882,424 (+86.27%) | View |
| 2024-11-14 3:30 pm Purchase | 13G | C4 THERAPEUTICS INC CCCC | Soleus Capital Master Fund L.P. | 6,603,996 9.400% | 4,048,000 (+158.37%) | View |
| 2024-06-07 08:30 am Purchase | 13G | Terns Pharmaceuticals Inc. TERN | Soleus Capital Master Fund L.P. | 3,341,120 5.200% | 3,341,120 (New Position) | View |
| 2024-02-09 10:32 am Purchase | 13G | Celcuity Inc. CELC | Soleus Capital Master Fund L.P. | 2,623,890 9.900% | 338,336 (+14.80%) | View |
| 2024-02-08 10:08 am Purchase | 13G | CalciMedica Inc. CALC | Soleus Capital Master Fund L.P. | 1,105,016 9.990% | 321,112 (+40.96%) | View |
| 2024-02-05 10:24 am Purchase | 13G | C4 THERAPEUTICS INC CCCC | Soleus Capital Master Fund L.P. | 2,555,996 5.200% | 720,000 (+39.22%) | View |
| 2024-02-02 09:59 am Sale | 13G | PALVELLA THERAPEUTICS INC. PVLA | Soleus Capital Master Fund L.P. | 0 0.000% | -4,000,000 (Position Closed) | View |
| 2024-02-02 09:56 am Purchase | 13G | RIGEL PHARMACEUTICALS INC RIGL | Soleus Capital Master Fund L.P. | 9,442,579 5.400% | 219,564 (+2.38%) | View |
| 2024-02-02 09:54 am Purchase | 13G | Organogenesis Holdings Inc. ORGO | Soleus Capital Master Fund L.P. | 8,963,000 6.800% | 1,599,937 (+21.73%) | View |
| 2024-02-02 09:53 am Sale | 13G | SURMODICS INC SRDX | Soleus Capital Master Fund L.P. | 771,700 5.400% | -3,611 (-0.47%) | View |
| 2024-02-02 09:50 am Purchase | 13G | Jasper Therapeutics Inc. JSPR | Soleus Capital Master Fund L.P. | 987,096 8.800% | 987,096 (New Position) | View |
| 2024-02-02 09:49 am Purchase | 13G | Verastem Inc. VSTM | Soleus Capital Master Fund L.P. | 1,425,634 6.800% | 128,265 (+9.89%) | View |
| 2024-02-02 09:44 am Sale | 13G | IRADIMED CORP IRMD | Soleus Capital Master Fund L.P. | 643,206 5.100% | -101,798 (-13.66%) | View |
| 2024-02-02 09:42 am Sale | 13G | VYNE Therapeutics Inc. VYNE | Soleus Capital Master Fund L.P. | 703,868 5.000% | -187,000 (-20.99%) | View |